Rome

• VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended
  2023-509233-39-00 4 2022-01-20 Moderately to Severely Active Ulcerative Colitis
• EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib … Ended
  2024-513023-17-00 5 2022-01-12 Treatment of acute graft-versus host disease (aGvHD) to the gastrointe
• A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu … Ended
  2023-507189-17-00 4 2022-01-09 Muscle-Invasive Urothelial Carcinoma of the Bladder
• Sotorasib (AMG 510) in Subjects with NSCLC with KRASG12C Mutation in Need of First-Line Treatment Ended
  2024-511189-36-00 4 2021-12-23 Non-small cell lung cancer (NSCLC)
• An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasth … Ended
  2024-510932-36-00 5 2021-12-21 Generalized Myasthenia Gravis (gMG)
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) Ended
  2023-509018-12-00 5 2021-12-17 Moderately to severely active Ulcerative Colitis (UC)
• Study for the research of predictive factors of response to Tofacitinib therapy in patients with ulcerative rectal colitis. Ended
  2024-518577-34-00 6 2021-12-16 Ulcerative colitis
• An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in … Ended
  2023-503406-36-00 4 2021-12-13 Male and female participants at least 18 years of age who are actively
• Clinical trial of MK-4280A for colorectal cancer that has spread after previous treatment Ended
  2024-511043-25-00 5 2021-11-30 Colorectal Cancer
• Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe … Ended
  2022-500752-39-00 5 2021-11-25 Prevention of Respiratory syncytial virus (RSV) infection in infants a
• A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two d … Ended
  2024-513940-27-00 4 2021-11-19 Chronic low back pain
• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 4 2021-11-08 Classical Hodgkin Lymphoma
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcu … Ended
  2024-511231-94-00 5 2021-10-27 Human Normal Immunoglobulin
• A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended
  2023-506170-12-00 4 2021-10-18 Alzheimer’s Disease
• A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease Ended
  2023-506897-11-00 5 2021-10-18 Non-diabetic chronic kidney disease
• A study to evaluate the efficacy and safety of repeating dose of benralizumab administered SC versus placebo in patients with Eosinophilic C … Ended
  2023-507987-38-00 5 2021-10-14 Severe CRSwNP patients with asthma.
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac … Ended
  2024-511066-36-00 5 2021-10-13 Light Chain (AL) Amyloidosis
• Asciminib treatment optimization in ≥ 3rd line CML-CP Ended
  2024-511381-36-00 5 2021-10-13 Chronic Myelogenous Leukemia in chronic phase (CML-CP)
• Proof-of-concept study for SAR445088 in chronic inflammatory demyelinating polyneuropathy (CIDP) Ended
  2024-512345-16-00 4 2021-10-13 Chronic inflammatory demyelinating polyradiculoneuropathy
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia … Ended
  2024-510744-31-00 5 2021-10-06 Giant cell arteritis (GCA)
• An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed … Ended
  2024-512717-41-00 4 2021-10-01 Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
• Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of pre-surgical HPV9-valente vaccination … Ended
  2024-513704-34-00 5 2021-10-01 cervical cancer

Showing 1,921–1,944 of 2,096 trials